Uncategorized
Kailera walks path paved by Lilly in post-IPO ‘catalyst-rich period’
Kailera Therapeutics is advancing a pipeline of weight loss medicines that mirror that of Eli Lilly’s: an injectable GLP-1/GIP dual agonist like Zepbound, an oral GLP-1 like Foundayo and a triple-G therapy like retatrutide.